

# Maria Domenica Cappellini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1761678/publications.pdf>

Version: 2024-02-01

392  
papers

20,834  
citations

12597

71  
h-index

16186

128  
g-index

399  
all docs

399  
docs citations

399  
times ranked

15760  
citing authors

#	ARTICLE	IF	CITATIONS
1	Morbidity-free survival and hemoglobin level in non-transfusion-dependent $\beta^2$ -thalassemia: a 10-year cohort study. <i>Annals of Hematology</i> , 2022, 101, 203-204.	0.8	21
2	Thalassemia and autoimmune diseases: Absence of evidence or evidence of absence?. <i>Blood Reviews</i> , 2022, 52, 100874.	2.8	6
3	Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	7
4	Mortality in $\beta^2$ -thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization. <i>Blood</i> , 2022, 139, 2080-2083.	0.6	10
5	Tricuspid-valve regurgitant jet velocity as a risk factor for death in $\beta^2$ -Thalassemia. <i>Haematologica</i> , 2022, , .	1.7	0
6	Thalassaemia is paradoxically associated with a reduced risk of in-hospital complications and mortality in COVID-19: Data from an international registry. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2520-2528.	1.6	6
7	Splenomegaly: Dare to think rare. <i>American Journal of Hematology</i> , 2022, 97, 1259-1265.	2.0	1
8	Redox Balance in $\beta^2$ -Thalassemia and Sickle Cell Disease: A Love and Hate Relationship. <i>Antioxidants</i> , 2022, 11, 967.	2.2	5
9	An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (<scp>THETIS</scp>): 5-year results. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	2
10	Pharmacological Induction of Fetal Hemoglobin in $\beta^2$ -Thalassemia and Sickle Cell Disease: An Updated Perspective. <i>Pharmaceuticals</i> , 2022, 15, 753.	1.7	14
11	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and $\beta^2$ -Thalassemia. <i>New England Journal of Medicine</i> , 2021, 384, 252-260.	13.9	939
12	Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later. <i>American Journal of Hematology</i> , 2021, 96, E54-E56.	2.0	28
13	$\beta^2$ -Thalassemias. <i>New England Journal of Medicine</i> , 2021, 384, 727-743.	13.9	183
14	Ferric carboxymaltose for sub-acute and chronic iron deficiency anemia in inherited platelet function defects. <i>Internal and Emergency Medicine</i> , 2021, 16, 505-507.	1.0	2
15	CYP450 Mediates Reactive Oxygen Species Production in a Mouse Model of $\beta^2$ -Thalassemia through an Increase in 20-HETE Activity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1106.	1.8	6
16	The use of luspatercept for thalassemia in adults. <i>Blood Advances</i> , 2021, 5, 326-333.	2.5	28
17	Variations in hemoglobin level and morbidity burden in non-transfusion-dependent $\beta^2$ -thalassemia. <i>Annals of Hematology</i> , 2021, 100, 1903-1905.	0.8	20
18	Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent $\beta^2$ -thalassaemia. <i>British Journal of Haematology</i> , 2021, 194, 474-477.	1.2	10

#	ARTICLE	IF	CITATIONS
19	Innovative Treatments for Rare Anemias. HemaSphere, 2021, 5, e576.	1.2	13
20	The EHA Research Roadmap: Anemias. HemaSphere, 2021, 5, e607.	1.2	7
21	Muscular deconditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major. American Journal of Hematology, 2021, 96, E370-E373.	2.0	1
22	Experts'™ views on COVID-19 vaccination and the impact of the pandemic on patients with Gaucher disease. British Journal of Haematology, 2021, 195, e135-e137.	1.2	3
23	Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in $\beta^2$ -thalassemia: current evidence and future clinical development. Expert Review of Hematology, 2021, 14, 633-644.	1.0	13
24	2021 update on clinical trials in $\beta^2$ -thalassemia. American Journal of Hematology, 2021, 96, 1518-1531.	2.0	38
25	Luspatercept for $\beta^2$ -thalassemia: beyond red blood cell transfusions. Expert Opinion on Biological Therapy, 2021, 21, 1363-1371.	1.4	14
26	Improving outcomes and quality of life for patients with transfusion-dependent $\beta^2$ -thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Review of Hematology, 2021, 14, 897-909.	1.0	13
27	Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia. Scientific Reports, 2021, 11, 2594.	1.6	12
28	Changing patterns of thalassaemia in Italy: a WebThal perspective. Blood Transfusion, 2021, 19, 261-268.	0.3	2
29	Inhibition of Fibroblast Growth Factor-23 (FGF-23) Rescues Bone and Hematopoietic Stem Cell Niche Defects in Beta-Thalassemia, Uncovering the Missing Link between Hematopoiesis and Bone. Blood, 2021, 138, 572-572.	0.6	1
30	Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent $\beta^2$ -Thalassemia in the BEYOND Trial. Blood, 2021, 138, 3081-3081.	0.6	4
31	Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review. Children, 2021, 8, 1104.	0.6	7
32	Advancing the care of $\beta^2$ -thalassaemia patients with novel therapies. Blood Transfusion, 2021, , .	0.3	1
33	Treatment with ferric carboxymaltose in stable patients with severe iron deficiency anemia in the emergency department. Internal and Emergency Medicine, 2020, 15, 629-634.	1.0	12
34	Management of age-associated medical complications in patients with $\beta^2$ -thalassemia. Expert Review of Hematology, 2020, 13, 85-94.	1.0	18
35	Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?. Expert Opinion on Investigational Drugs, 2020, 29, 23-31.	1.9	15
36	A new approach for anemia in kidney disease. European Journal of Internal Medicine, 2020, 71, 1-3.	1.0	3

#	ARTICLE	IF	CITATIONS
37	Parkinson's disease in Gaucher disease patients: what's changing in the counseling and management of patients and their relatives?. Orphanet Journal of Rare Diseases, 2020, 15, 262.	1.2	3
38	Fyn specifically Regulates the activity of red cell glucose-6-phosphate-dehydrogenase. Redox Biology, 2020, 36, 101639.	3.9	14
39	Clinical and molecular epidemiology of erythropoietic protoporphyria in Italy. European Journal of Dermatology, 2020, 30, 532-540.	0.3	10
40	Inherited microcytic anemias. Hematology American Society of Hematology Education Program, 2020, 2020, 465-470.	0.9	12
41	Recommendations for Pregnancy in Rare Inherited Anemias. HemaSphere, 2020, 4, e446.	1.2	8
42	Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. Liver International, 2020, 40, 3061-3070.	1.9	13
43	A holistic approach to iron chelation therapy in transfusion-dependent thalassemia patients with serum ferritin below 500 µg/L. American Journal of Hematology, 2020, 95, E230-E232.	2.0	2
44	Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations. American Journal of Hematology, 2020, 95, E208-E210.	2.0	24
45	Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation. Drugs, 2020, 80, 1053-1063.	4.9	49
46	A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent $\beta^2$ -Thalassemia. New England Journal of Medicine, 2020, 382, 1219-1231.	13.9	177
47	Hyperferritinemia and diagnosis of type 1 Gaucher disease. American Journal of Hematology, 2020, 95, 570-576.	2.0	6
48	Less "reds" more "blues": hemoglobin level and depression in non-transfusion-dependent thalassemia. Annals of Hematology, 2020, 99, 903-904.	0.8	9
49	Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist. Digestive and Liver Disease, 2020, 52, 368-373.	0.4	15
50	SARS-CoV-2 infection in beta thalassemia: Preliminary data from the Italian experience. American Journal of Hematology, 2020, 95, E198-E199.	2.0	56
51	Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. Blood, 2020, 136, 8-9.	0.6	7
52	Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with $\beta^2$ -Thalassemia in the Believe Trial. Blood, 2020, 136, 47-48.	0.6	8
53	Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in $\beta^2$ -Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial. Blood, 2020, 136, 45-46.	0.6	8
54	Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited. Internal and Emergency Medicine, 2019, 14, 365-370.	1.0	13

#	ARTICLE	IF	CITATIONS
55	Quality of life in patients with $\beta^2$ -thalassemia: A prospective study of transfusion-dependent and non-transfusion-dependent patients in Greece, Italy, Lebanon, and Thailand. <i>American Journal of Hematology</i> , 2019, 94, E261-E264.	2.0	21
56	UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E283-E285.	2.0	4
57	Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent $\beta^0$ -thalassemia. <i>Nature Medicine</i> , 2019, 25, 234-241.	15.2	188
58	Current challenges in the management of patients with sickle cell disease – A report of the Italian experience. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 120.	1.2	24
59	Oocyte quality in women with thalassaemia major: insights from IVF cycles. <i>European Journal of Obstetrics and Gynecology and Reproductive Biology: X</i> , 2019, 3, 100048.	0.6	6
60	Development of a thalassemia-related thrombosis risk scoring system. <i>American Journal of Hematology</i> , 2019, 94, E207-E209.	2.0	7
61	Iron overload in congenital haemolytic anaemias: role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation. <i>British Journal of Haematology</i> , 2019, 185, 523-531.	1.2	6
62	Diagnosis of chronic anaemia in gastrointestinal disorders: A guideline by the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Society of Paediatric Gastroenterology Hepatology and Nutrition (SIGENP). <i>Digestive and Liver Disease</i> , 2019, 51, 471-483.	0.4	21
63	EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. <i>HemaSphere</i> , 2019, 3, e208.	1.2	13
64	Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO <sup>®</sup> ). <i>American Journal of Hematology</i> , 2019, 94, 171-176.	2.0	7
65	Validation of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO <sup>®</sup> ). <i>American Journal of Hematology</i> , 2019, 94, 177-183.	2.0	7
66	Sotatercept, a novel transforming growth factor $\beta^2$ ligand trap, improves anemia in $\beta^2$ -thalassemia: a phase II, open-label, dose-finding study. <i>Haematologica</i> , 2019, 104, 477-484.	1.7	61
67	Common fetal hemoglobin variants in Lebanese patients bearing the codon 29 beta gene mutation associated with different thalassemia phenotypes. <i>Annals of Hematology</i> , 2019, 98, 833-840.	0.8	0
68	Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial. <i>Blood</i> , 2019, 134, 2245-2245.	0.6	7
69	Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions. <i>Blood</i> , 2019, 134, 3545-3545.	0.6	3
70	Selecting $\beta^0$ -Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm. <i>Blood</i> , 2019, 134, 972-972.	0.6	2
71	Microcytosis is important in screening of iron deficiency anemia. <i>European Journal of Internal Medicine</i> , 2018, 48, e39.	1.0	0
72	A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?. <i>Blood Reviews</i> , 2018, 32, 300-311.	2.8	95

#	ARTICLE	IF	CITATIONS
73	Hypercoagulability and Vascular Disease. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 237-245.	0.9	20
74	Clinical Complications and Their Management. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 223-236.	0.9	14
75	Low-dose Synacthen test with measurement of salivary cortisol in adult patients with $\beta^2$ -thalassemia major. <i>Endocrine</i> , 2018, 60, 348-354.	1.1	5
76	An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia. <i>Internal and Emergency Medicine</i> , 2018, 13, 1233-1238.	1.0	0
77	Thalassaemia. <i>Lancet, The</i> , 2018, 391, 155-167.	6.3	512
78	What is behind a relapse of thrombotic thrombocytopenic purpura?. <i>Internal and Emergency Medicine</i> , 2018, 13, 709-712.	1.0	1
79	Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 69, 82-89.	0.6	34
80	How I manage medical complications of $\beta^2$ -thalassemia in adults. <i>Blood</i> , 2018, 132, 1781-1791.	0.6	78
81	Non-transferrin-bound iron and oxidative stress during allogeneic hemopoietic stem cell transplantation in patients with or without iron overload. <i>American Journal of Hematology</i> , 2018, 93, E250-E252.	2.0	15
82	Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. <i>International Journal of Molecular Sciences</i> , 2018, 19, 182.	1.8	46
83	Circulating cell-free DNA and ineffective erythropoiesis in nontransfusion-dependent $\beta^2$ -thalassemia. <i>American Journal of Hematology</i> , 2018, 93, E365-E368.	2.0	2
84	Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 64-72.	0.5	18
85	Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessment. <i>PLoS ONE</i> , 2018, 13, e0192890.	1.1	51
86	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. <i>Blood</i> , 2018, 132, 163-163.	0.6	11
87	Sickle cell maculopathy: Identification of systemic risk factors, and microstructural analysis of individual retinal layers of the macula. <i>PLoS ONE</i> , 2018, 13, e0193582.	1.1	22
88	The role of cardiac magnetic resonance in assessing the cardiac involvement in Gaucher type 1 patients. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 244-248.	0.6	9
89	Reply to Management of hepatocellular carcinoma in thalassemia and importance of the human factor. <i>Cancer</i> , 2017, 123, 1073-1073.	2.0	1
90	Anemia is a mortality prognostic factor in patients initially hospitalized for acute heart failure. <i>Internal and Emergency Medicine</i> , 2017, 12, 749-756.	1.0	27

#	ARTICLE	IF	CITATIONS
91	Pregnancy in $\beta$ -thalassemia intermedia at two tertiary care centers in Lebanon and Italy: A follow-up report on fetal and maternal outcomes. <i>American Journal of Hematology</i> , 2017, 92, E96-E99.	2.0	6
92	Hematologic malignancies in thalassemia: Adding new cases to the repertoire. <i>American Journal of Hematology</i> , 2017, 92, E68-E70.	2.0	6
93	A higher prevalence of hematologic malignancies in patients with thalassemia: Background and culprits. <i>American Journal of Hematology</i> , 2017, 92, 414-416.	2.0	11
94	Myocardial deformation in iron overload cardiomyopathy: speckle tracking imaging in a beta-thalassemia major population. <i>Internal and Emergency Medicine</i> , 2017, 12, 799-809.	1.0	30
95	Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. <i>Cancer</i> , 2017, 123, 751-758.	2.0	54
96	Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. <i>British Journal of Haematology</i> , 2017, 176, 288-299.	1.2	43
97	Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. <i>European Journal of Internal Medicine</i> , 2017, 42, 16-23.	1.0	76
98	Investigational drugs in phase I and phase II clinical trials for thalassemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 793-802.	1.9	21
99	Recommendations regarding splenectomy in hereditary hemolytic anemias. <i>Haematologica</i> , 2017, 102, 1304-1313.	1.7	138
100	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. <i>American Journal of Hematology</i> , 2017, 92, 1068-1078.	2.0	290
101	Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced <i>in vivo</i> homing capacity compared to plerixafor alone. <i>Haematologica</i> , 2017, 102, e120-e124.	1.7	33
102	Serum ferritin values between 300 and 800 ng/mL in nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. <i>American Journal of Hematology</i> , 2017, 92, E35-E37.	2.0	13
103	Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. <i>American Journal of Hematology</i> , 2017, 92, 1349-1355.	2.0	42
104	Decompensated Cirrhosis and Sickle Cell Disease: Case Reports and Review of the Literature. <i>Hemoglobin</i> , 2017, 41, 131-133.	0.4	5
105	Pulmonary dysfunction in thalassaemia major: is there any relationship with body iron stores?. <i>British Journal of Haematology</i> , 2017, 176, 309-314.	1.2	9
106	One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2017, 64, 188-196.	0.8	24
107	The Role of Trabecular Bone Score and Hip Geometry in Thalassemia Major: A Neural Network Analysis. <i>British Journal of Research</i> , 2017, 04, .	0.1	1
108	Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2778.	1.8	20

#	ARTICLE	IF	CITATIONS
109	Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-12.	0.8	25
110	New therapeutic targets in transfusion-dependent and -independent thalassemia. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 278-283.	0.9	35
111	Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 4073-4078.	2.0	15
112	Deferasirox: an orphan drug for chronic iron overload in non-transfusion dependent thalassemia syndromes. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 677-686.	0.5	2
113	A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia. <i>European Journal of Haematology</i> , 2016, 96, 352-359.	1.1	34
114	A giant adrenal myelolipoma in a beta-thalassemia major patient: Does ineffective erythropoiesis play a role?. <i>American Journal of Hematology</i> , 2016, 91, 1281-1282.	2.0	5
115	Ferroportin expression and regulation in non-transfusion dependent thalassemia. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 58, 26-28.	0.6	0
116	X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria. <i>Clinical Genetics</i> , 2016, 89, 20-26.	1.0	25
117	Laboratory diagnosis of thalassemia. <i>International Journal of Laboratory Hematology</i> , 2016, 38, 32-40.	0.7	120
118	Standardization of MRI and Scintigraphic Scores for Assessing the Severity of Bone Marrow Involvement in Adult Patients With Type 1 Gaucher Disease. <i>American Journal of Roentgenology</i> , 2016, 206, 1245-1252.	1.0	11
119	When diagnostics meets translational research: detection of hemoglobin fractions in cellular lysates from in vitro erythroid cultures by Capillarys 2 Flex Piercing analyzer (Sebia). <i>Translational Research</i> , 2016, 169, 31-39.e4.	2.2	2
120	Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. <i>European Journal of Haematology</i> , 2016, 96, 19-26.	1.1	27
121	Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 57, 23-29.	0.6	24
122	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	1.7	67
123	Bone turnover and mineral density in adult thalassaemic patients: relationships with growth hormone secretory status and circulating somatomedins. <i>Endocrine</i> , 2016, 53, 551-557.	1.1	8
124	Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. <i>European Journal of Internal Medicine</i> , 2016, 28, 91-96.	1.0	14
125	New insights into transfusion-related iron toxicity: Implications for the oncologist. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 261-271.	2.0	46
126	Disorders of Hemoglobin Synthesis: Pathophysiology and Diagnostic Evaluation. , 2016, , 29-37.		0



#	ARTICLE	IF	CITATIONS
127	Myocardial and Hepatic Iron Overload Assessment by Region-Based and Pixel-Wise T2* Mapping Analysis. <i>Journal of Computer Assisted Tomography</i> , 2015, 39, 128-133.	0.5	6
128	Evidence of non-transferrin-bound iron in patients with ST-elevation myocardial infarction: relationship with microvascular obstruction and post-reperfusion myocardial hemorrhage. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2015, 17, P118.	1.6	0
129	Treating hepatitis C in patients with hemoglobinopathies. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1267-1278.	0.5	0
130	Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications. <i>Leukemia Research</i> , 2015, 39, 88-91.	0.4	18
131	The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment. <i>American Journal of Hematology</i> , 2015, 90, 306-309.	2.0	32
132	Does TMPRSS6 RS855791 Polymorphism Contribute to Iron Deficiency in Treated Celiac Disease?. <i>American Journal of Gastroenterology</i> , 2015, 110, 200-202.	0.2	23
133	Hemoglobin level and morbidity in non-transfusion-dependent thalassemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 108-109.	0.6	20
134	Anemia in Clinical Practice—Definition and Classification: Does Hemoglobin Change With Aging?. <i>Seminars in Hematology</i> , 2015, 52, 261-269.	1.8	257
135	Molecular Basis of $\beta^2$ -Thalassemia Intermedia in Erbil Province of Iraqi Kurdistan. <i>Hemoglobin</i> , 2015, 39, 178-183.	0.4	20
136	Anemia in elderly hospitalized patients: prevalence and clinical impact. <i>Internal and Emergency Medicine</i> , 2015, 10, 581-586.	1.0	53
137	Congenital erythropoietic porphyria linked to $GATA1$ $R216W$ mutation: challenges for diagnosis. <i>European Journal of Haematology</i> , 2015, 94, 491-497.	1.1	39
138	Anemia and splenomegaly: what lies behind?. <i>Internal and Emergency Medicine</i> , 2015, 10, 711-714.	1.0	0
139	Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. <i>Blood</i> , 2015, 125, 3868-3877.	0.6	67
140	Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. <i>British Journal of Haematology</i> , 2015, 168, 284-290.	1.2	50
141	Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent $\beta^2$ thalassaemia. <i>British Journal of Haematology</i> , 2015, 168, 882-890.	1.2	27
142	Role of Non-Transferrin-Bound Iron in the pathogenesis of cardiotoxicity in patients with ST-elevation myocardial infarction assessed by Cardiac Magnetic Resonance Imaging. <i>International Journal of Cardiology</i> , 2015, 199, 326-332.	0.8	16
143	Hyponatremia: a challenge for internists. <i>Internal and Emergency Medicine</i> , 2015, 10, 973-976.	1.0	0
144	Growth Differentiation Factor 15 expression and regulation during erythroid differentiation in non-transfusion dependent thalassemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 26-28.	0.6	10

#	ARTICLE	IF	CITATIONS
145	Management of Bone Disease in Gaucher Disease Type 1: Clinical Practice. <i>Advances in Therapy</i> , 2014, 31, 1197-1212.	1.3	29
146	Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. <i>Haematologica</i> , 2014, 99, 811-820.	1.7	302
147	Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. <i>Haematologica</i> , 2014, 99, 267-275.	1.7	89
148	Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. <i>British Journal of Haematology</i> , 2014, 167, 121-126.	1.2	69
149	Deferasirox for cardiac siderosis in $\beta^2$ -thalassaemia major: a multicentre, open label, prospective study. <i>British Journal of Haematology</i> , 2014, 167, 423-426.	1.2	7
150	Modulation of gamma globin genes expression by histone deacetylase inhibitors: an <i>in vitro</i> study. <i>British Journal of Haematology</i> , 2014, 165, 714-721.	1.2	18
151	Development of interactive algorithm for clinical management of acute events related to sickle cell disease in emergency department. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 91.	1.2	14
152	Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up. <i>Haematologica</i> , 2014, 99, e17-e18.	1.7	14
153	Thalassemic osteopathy: A new marker of bone deposition. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 52, 91-94.	0.6	10
154	Remission of autoimmune hyperthyroidism after chemotherapy for cancer. <i>Internal and Emergency Medicine</i> , 2014, 9, 109-111.	1.0	1
155	Bone disease in adult patients with $\beta^2$ -thalassaemia major: a case-control study. <i>Internal and Emergency Medicine</i> , 2014, 9, 59-63.	1.0	11
156	An overview of current treatment strategies for $\beta^2$ -thalassemia. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 665-679.	0.5	8
157	A challenging diagnosis for potential fatal diseases: Recommendations for diagnosing acute porphyrias. <i>European Journal of Internal Medicine</i> , 2014, 25, 497-505.	1.0	34
158	Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 52, 88-90.	0.6	8
159	Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of $\beta^2$ -Thalassemia Patients Using Right Heart Catheterization. <i>Circulation</i> , 2014, 129, 338-345.	1.6	101
160	Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. <i>European Journal of Haematology</i> , 2014, 92, 521-526.	1.1	17
161	Management of Non-Transfusion-Dependent Thalassemia: A Practical Guide. <i>Drugs</i> , 2014, 74, 1719-1729.	4.9	10
162	Validity of $\beta^2$ -d-glucosidase activity measured in dried blood samples for detection of potential Gaucher disease patients. <i>Clinical Biochemistry</i> , 2014, 47, 1293-1296.	0.8	16

#	ARTICLE	IF	CITATIONS
163	Priapism, an Emerging Complication in $\hat{\beta}^2$ -Thalassemia Intermedia Patients. Hemoglobin, 2014, 38, 351-354.	0.4	7
164	Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis <scp>C</scp> patients. Journal of Viral Hepatitis, 2014, 21, 416-423.	1.0	11
165	The Spectrum of Ocular Alterations in Patients with $\hat{\beta}^2$ -Thalassemia Syndromes Suggests a Pathology Similar to Pseudoxanthoma Elasticum. Ophthalmology, 2014, 121, 709-718.	2.5	37
166	Serum ferritin level and morbidity risk in transfusion-independent patients with $\hat{\beta}$ -thalassemia intermedia: the ORIENT study. Haematologica, 2014, 99, e218-e221.	1.7	56
167	Thalassemic erythrocytes release microparticles loaded with hemichromes by redox activation of p72Syk kinase. Haematologica, 2014, 99, 570-578.	1.7	52
168	An Update on Thalassemia Intermedia. Journal Medical Libanais, 2014, 61, 175-182.	0.0	10
169	Antibodies reacting with Simian virus 40 mimotopes in serum samples from patients with thalassaemia major. Blood Transfusion, 2014, 12, 464-70.	0.3	4
170	Treating iron overload in patients with non- $\hat{\beta}$ -transfusion-dependent thalassemia. American Journal of Hematology, 2013, 88, 409-415.	2.0	67
171	Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Annals of Hematology, 2013, 92, 1485-1493.	0.8	64
172	Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non- $\hat{\beta}$ -transfusion-dependent thalassemia patients. American Journal of Hematology, 2013, 88, 503-506.	2.0	16
173	Epidemiology of Clostridium difficile-associated disease in internal medicine wards in northern Italy. Internal and Emergency Medicine, 2013, 8, 717-723.	1.0	22
174	Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. Expert Review of Hematology, 2013, 6, 495-509.	1.0	9
175	Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with $\hat{\beta}^2$ -thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2013, 51, 35-38.	0.6	47
176	Assessment and management of iron overload in $\hat{\beta}^2$ -thalassaemia major patients during the 21st century: a real-life experience from the <scp>I</scp>-talian <scp>W</scp>-ebthal project. British Journal of Haematology, 2013, 161, 872-883.	1.2	31
177	Challenges in dealing with a cirrhotic patient. Internal and Emergency Medicine, 2013, 8, 161-164.	1.0	0
178	Prolonged PT and aPTT in a patient with severe proteinuria. Internal and Emergency Medicine, 2013, 8, 611-614.	1.0	0
179	A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrology Dialysis Transplantation, 2013, 28, 1733-1743.	0.4	47
180	Iron overload in $\hat{\beta}^2$ -thalassemia intermedia. Current Opinion in Hematology, 2013, 20, 187-192.	1.2	42

#	ARTICLE	IF	CITATIONS
181	Very high frequency of <i>TMPRSS6</i> gene variations in iron deficiency anaemia of patients with polyendocrine autoimmune syndromes: more than a casual association?. <i>British Journal of Haematology</i> , 2013, 161, 147-150.	1.2	3
182	Mosaic segmental uniparental isodisomy and progressive clonal selection: a common mechanism of late onset $\alpha$ -thalassemia major. <i>Haematologica</i> , 2013, 98, 691-695.	1.7	11
183	Clinical experience with fetal hemoglobin induction therapy in patients with $\beta^0$ -thalassemia. <i>Blood</i> , 2013, 121, 2199-2212.	0.6	154
184	Altered iron homeostasis in an animal model of hypertensive nephropathy. <i>Journal of Hypertension</i> , 2013, 31, 2259-2269.	0.3	7
185	Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: A closer look at the role of siderosis. <i>Annals of Hepatology</i> , 2013, 12, 142-146.	0.6	46
186	Transcranial Color Doppler Sonography and Magnetic Resonance Imaging In Adult Patients With Sickle Cell Disease. <i>Blood</i> , 2013, 122, 2245-2245.	0.6	1
187	Deferasirox "Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION). <i>Blood</i> , 2013, 122, 2257-2257.	0.6	5
188	Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. <i>Blood Transfusion</i> , 2013, 11, 108-22.	0.3	17
189	Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. <i>Annals of Hepatology</i> , 2013, 12, 142-6.	0.6	18
190	The Thalassemias. , 2012, , 1060-1066.		0
191	Thyroid Cancer in $\beta^0$ -Thalassemia. <i>Hemoglobin</i> , 2012, 36, 407-408.	0.4	5
192	Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with $\alpha$ -thalassemia major. <i>Haematologica</i> , 2012, 97, 842-848.	1.7	122
193	Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in $\beta^0$ -Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial. <i>Anemia</i> , 2012, 2012, 1-10.	0.5	52
194	$\beta^0$ -Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life. <i>Anemia</i> , 2012, 2012, 1-1.	0.5	38
195	Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. <i>Blood</i> , 2012, 120, 970-977.	0.6	115
196	How I treat transfusional iron overload. <i>Blood</i> , 2012, 120, 3657-3669.	0.6	168
197	Does absolute excess of alpha chains compromise the benefit of splenectomy in patients with thalassemia intermedia?. <i>Haematologica</i> , 2012, 97, 151-153.	1.7	5
198	Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia. <i>Blood Reviews</i> , 2012, 26, S1-S2.	2.8	13

#	ARTICLE	IF	CITATIONS
199	Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. <i>Blood Reviews</i> , 2012, 26, S16-S19.	2.8	105
200	Hypercoagulability in non-transfusion-dependent thalassemia. <i>Blood Reviews</i> , 2012, 26, S20-S23.	2.8	44
201	Contemporary approaches to treatment of beta-thalassemia intermedia. <i>Blood Reviews</i> , 2012, 26, S24-S27.	2.8	40
202	Seven novel genetic mutations within the 5'UTR and the housekeeping promoter of HMBS gene responsible for the non-erythroid form of acute intermittent porphyria. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 49, 147-151.	0.6	12
203	Minimal disease activity in Gaucher disease: Criteria for definition. <i>Molecular Genetics and Metabolism</i> , 2012, 107, 521-525.	0.5	4
204	Abnormal Fundus Autofluorescence Results of Patients in Long-term Treatment with Deferoxamine. <i>Ophthalmology</i> , 2012, 119, 1693-1700.	2.5	39
205	Hypercoagulability in $\beta^0$ -thalassemia: a status quo. <i>Expert Review of Hematology</i> , 2012, 5, 505-512.	1.0	70
206	Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with $\beta^0$ -thalassemia intermedia. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 49, 136-139.	0.6	42
207	What does acute dyspnea hide?. <i>Internal and Emergency Medicine</i> , 2012, 7, 353-358.	1.0	1
208	Fetal hemoglobin levels and morbidity in untransfused patients with $\beta^0$ -thalassemia intermedia. <i>Blood</i> , 2012, 119, 364-367.	0.6	85
209	Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. <i>Annals of Hematology</i> , 2012, 91, 1443-1449.	0.8	41
210	Neridronate improves bone mineral density and reduces back pain in $\beta^0$ -thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. <i>British Journal of Haematology</i> , 2012, 158, 274-282.	1.2	36
211	Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years. <i>British Journal of Haematology</i> , 2012, 158, 528-538.	1.2	33
212	Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial. <i>Movement Disorders</i> , 2012, 27, 446-449.	2.2	57
213	Serum Ferritin Levels and Morbidity in $\beta^0$ -Thalassemia Intermedia: A 10-Year Cohort Study. <i>Blood</i> , 2012, 120, 1021-1021.	0.6	11
214	Evaluation of the 5 Mg/g Liver Iron Concentration Threshold and Its Association with Vascular and Endocrine/Bone Morbidity in $\beta^0$ -Thalassemia Intermedia. <i>Blood</i> , 2012, 120, 1024-1024.	0.6	1
215	Two-Year Renal Hemodynamic Effects of Deferasirox in Patients with Transfusion-Dependent $\beta^0$ -Thalassemia. <i>Blood</i> , 2012, 120, 3257-3257.	0.6	2
216	Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA). <i>Blood</i> , 2012, 120, 3258-3258.	0.6	3

#	ARTICLE	IF	CITATIONS
217	An update on iron chelation therapy. <i>Blood Transfusion</i> , 2012, 10, 411-22.	0.3	164
218	A Heparin Inhibitor Mobilizes Iron for Incorporation Into Red Blood Cells in an Adenine-Induced Chronic Kidney Disease Model in Rats.. <i>Blood</i> , 2012, 120, 2082-2082.	0.6	0
219	Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in $\beta$ -thalassemic erythropoiesis. <i>Haematologica</i> , 2011, 96, 1595-1604.	1.7	63
220	Improvement in Liver Pathology of Patients With $\beta$ -Thalassemia Treated With Deferasirox for at Least 3 Years. <i>Gastroenterology</i> , 2011, 141, 1202-1211.e3.	0.6	73
221	Risk factors for pulmonary hypertension in patients with $\beta$ thalassemia intermedia. <i>European Journal of Internal Medicine</i> , 2011, 22, 607-610.	1.0	56
222	Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 47, 166-175.	0.6	50
223	Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with $\beta$ thalassemia intermedia. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 47, 232-234.	0.6	55
224	Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes. <i>PLoS ONE</i> , 2011, 6, e23109.	1.1	95
225	Optimal management of $\beta$ thalassaemia intermedia. <i>British Journal of Haematology</i> , 2011, 152, 512-523.	1.2	187
226	An unusual febrile nonhemolytic reaction occurred after transfusion in a thalassemia major patient with asymptomatic <i>Plasmodium falciparum</i> infection. <i>Transfusion</i> , 2011, 51, 469-472.	0.8	3
227	Congenital Dyserythropoietic Anemia Type II: molecular analysis and expression of the SEC23B Gene. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 89.	1.2	17
228	A reappraisal of Gaucher disease's diagnosis and disease management algorithms. <i>American Journal of Hematology</i> , 2011, 86, 110-115.	2.0	135
229	Changing patterns of splenectomy in transfusion-dependent thalassemia patients. <i>American Journal of Hematology</i> , 2011, 86, 808-810.	2.0	32
230	Thrombosis and Sickle Cell Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 226-236.	1.5	146
231	Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. <i>Blood</i> , 2011, 118, 884-893.	0.6	181
232	A highly conserved SOX6 double binding site mediates SOX6 gene downregulation in erythroid cells. <i>Nucleic Acids Research</i> , 2011, 39, 486-501.	6.5	76
233	Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study. <i>European Journal of Echocardiography</i> , 2011, 12, 242-246.	2.3	16
234	Elevated liver iron concentration is a marker of increased morbidity in patients with $\beta$ thalassemia intermedia. <i>Haematologica</i> , 2011, 96, 1605-1612.	1.7	153

#	ARTICLE	IF	CITATIONS
235	Continued improvement in myocardial T2* over two years of deferasirox therapy in $\hat{\alpha}$ -thalassemia major patients with cardiac iron overload. <i>Haematologica</i> , 2011, 96, 48-54.	1.7	70
236	Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study. <i>Blood</i> , 2011, 118, 902-902.	0.6	2
237	Improvement of Cardiac Function and Cardiac Volumes in Patients Treated with Deferasirox. <i>Blood</i> , 2011, 118, 2159-2159.	0.6	2
238	Efficacy of deferasirox in reducing and preventing cardiac iron overload in $\hat{\alpha}$ -thalassemia. <i>Blood</i> , 2010, 115, 2364-2371.	0.6	168
239	Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. <i>Annals of Hematology</i> , 2010, 89, 585-589.	0.8	55
240	Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. <i>Annals of Hematology</i> , 2010, 89, 1207-1213.	0.8	40
241	Selective toxicity of dihydroartemisinin on human CD34+ erythroid cell differentiation. <i>Toxicology</i> , 2010, 276, 128-134.	2.0	27
242	An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial. <i>Advances in Therapy</i> , 2010, 27, 533-546.	1.3	11
243	Hepcidin mutation in a $\hat{\alpha}$ -thalassemia major patient with persistent severe iron overload despite chelation therapy. <i>Internal and Emergency Medicine</i> , 2010, 5, 83-85.	1.0	3
244	Porphyrias at a glance: diagnosis and treatment. <i>Internal and Emergency Medicine</i> , 2010, 5, 73-80.	1.0	18
245	Correction of $\hat{\alpha}$ -thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. <i>EMBO Molecular Medicine</i> , 2010, 2, 315-328.	3.3	82
246	Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. <i>American Journal of Hematology</i> , 2010, 85, 288-290.	2.0	61
247	Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. <i>American Journal of Hematology</i> , 2010, 85, 564-568.	2.0	40
248	Renal complications in transfusion-dependent beta thalassaemia. <i>Blood Reviews</i> , 2010, 24, 239-244.	2.8	70
249	Age-related complications in treatment-naïve patients with thalassaemia intermedia. <i>British Journal of Haematology</i> , 2010, 150, 486-489.	1.2	100
250	Genetic variability of <i>TMPRSS6</i> and its association with iron deficiency anaemia. <i>British Journal of Haematology</i> , 2010, 151, 281-284.	1.2	33
251	Redefining thalassemia as a hypercoagulable state. <i>Annals of the New York Academy of Sciences</i> , 2010, 1202, 231-236.	1.8	78
252	The pituitary-adrenal axis in adult thalassaemic patients. <i>European Journal of Endocrinology</i> , 2010, 162, 43-48.	1.9	23

#	ARTICLE	IF	CITATIONS
253	Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. <i>Haematologica</i> , 2010, 95, 557-566.	1.7	260
254	Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. <i>Blood</i> , 2010, 115, 1886-1892.	0.6	315
255	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. <i>Blood</i> , 2010, 116, 2875-2883.	0.6	79
256	A validated disease severity scoring system for adults with type 1 Gaucher disease. <i>Genetics in Medicine</i> , 2010, 12, 44-51.	1.1	66
257	EPO Receptor Gain-of-Function Causes Hereditary Polycythemia, Alters CD34+ Cell Differentiation and Increases Circulating Endothelial Precursors. <i>PLoS ONE</i> , 2010, 5, e12015.	1.1	23
258	Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 4250-4250.	0.6	0
259	Pregnant women affected by thalassemia major: a controlled study of traits and personality. <i>Journal of Research in Medical Sciences</i> , 2010, 15, 100-6.	0.4	6
260	Update on the use of deferasirox in the management of iron overload. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 857.	0.9	27
261	A novel large deletion and three polymorphisms in the FECH gene associated with erythropoietic protoporphyria. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 44-6.	1.4	5
262	Multiplex ligation-dependent probe amplification: a novel approach for genetic diagnosis of Porphyria. <i>Journal of Human Genetics</i> , 2009, 54, 479-487.	1.1	13
263	Cholelithiasis in thalassemia major. <i>European Journal of Haematology</i> , 2009, 82, 22-25.	1.1	29
264	High nontransferrin bound iron levels and heart disease in thalassemia major. <i>American Journal of Hematology</i> , 2009, 84, 29-33.	2.0	128
265	Mutation analysis of hepcidin and ferroportin genes in Italian prospective blood donors with iron overload. <i>American Journal of Hematology</i> , 2009, 84, 592-593.	2.0	7
266	Paralytic Ileus and Liver Failure—An Unusual Presentation of Advanced Erythropoietic Protoporphyria. <i>Digestive Diseases and Sciences</i> , 2009, 54, 411-415.	1.1	12
267	The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine. <i>Internal and Emergency Medicine</i> , 2009, 4, 297-308.	1.0	31
268	Levels of non-transferrin bound iron as an index of iron overload in patients with thalassaemia intermedia. <i>British Journal of Haematology</i> , 2009, 146, 569-572.	1.2	66
269	Pregnancy and risk of venous thromboembolism in developing countries. <i>British Journal of Haematology</i> , 2009, 146, 691-692.	1.2	0
270	Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. <i>British Journal of Haematology</i> , 2009, 147, 634-640.	1.2	71



#	ARTICLE	IF	CITATIONS
271	Efficacy and safety of deferasirox doses of $\geq 30$ mg/kg per d in patients with transfusion-dependent anaemia and iron overload. <i>British Journal of Haematology</i> , 2009, 147, 752-759.	1.2	101
272	Assessment of Mitoxantrone-Induced Cardiotoxicity in Patients with Multiple Sclerosis: A Tissue Doppler Echocardiographic Analysis. <i>Echocardiography</i> , 2009, 26, 397-402.	0.3	10
273	Neuropsychological functions and metabolic aspects in subclinical hypothyroidism: The effects of l-thyroxine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 854-859.	2.5	23
274	Oral Iron Chelators. <i>Annual Review of Medicine</i> , 2009, 60, 25-38.	5.0	88
275	Thalassaemia Intermedia: an Update. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009004.	0.5	34
276	Insight onto the Pathophysiology and Clinical Complications of Thalassemia Intermedia. <i>Hemoglobin</i> , 2009, 33, S145-S159.	0.4	33
277	Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone. <i>Hemoglobin</i> , 2009, 33, S58-S69.	0.4	33
278	Case study on monoclonal gammopathy of undetermined significance/multiple myeloma. <i>Clinical Therapeutics</i> , 2009, 31, S181.	1.1	0
279	Hypercoagulability in splenectomized thalassaemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. <i>Haematologica</i> , 2009, 94, 1520-1527.	1.7	74
280	Efficacy and Safety of Deferasirox (Exjade <sup>®</sup> ) in $\beta^2$ -Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study. <i>Blood</i> , 2009, 114, 4062-4062.	0.6	4
281	Efficacy and Safety of Deferasirox (Exjade <sup>®</sup> ) in Patients with $\beta^2$ -Thalassemia Major Treated for up to 5 Years. <i>Blood</i> , 2009, 114, 4063-4063.	0.6	5
282	Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload. <i>Blood</i> , 2009, 114, 5111-5111.	0.6	1
283	COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009029.	0.5	19
284	Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. <i>European Journal of Haematology</i> , 2008, 80, 168-176.	1.1	210
285	Unusual association of a pituitary adenoma and a neurological emergency: case report and diagnostic steps. <i>Internal and Emergency Medicine</i> , 2008, 3, 297-300.	1.0	0
286	Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. <i>Internal and Emergency Medicine</i> , 2008, 3, 339-343.	1.0	79
287	Introduction. <i>Blood Reviews</i> , 2008, 22, S13.	2.8	2
288	Long-term efficacy and safety of deferasirox. <i>Blood Reviews</i> , 2008, 22, S35-S41.	2.8	69

#	ARTICLE	IF	CITATIONS
289	Myocardial involvement during the early course of type 2 diabetes mellitus: usefulness of Myocardial Performance Index. <i>Cardiovascular Ultrasound</i> , 2008, 6, 27.	0.5	17
290	Stroke in thalassemia: A dilemma. <i>American Journal of Hematology</i> , 2008, 83, 343-343.	2.0	18
291	Thalassemia and hypercoagulability. <i>Blood Reviews</i> , 2008, 22, 283-292.	2.8	143
292	Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-1 at different skeletal sites. <i>Clinical Endocrinology</i> , 2008, 69, 202-207.	1.2	36
293	Costs, quality of life, treatment satisfaction and compliance in patients with $\beta^2$ -thalassemia major undergoing iron chelation therapy: the ITHACA study. <i>Current Medical Research and Opinion</i> , 2008, 24, 1905-1917.	0.9	101
294	Erythroid differentiation and maturation from peripheral CD34+ cells in liquid culture: Cellular and molecular characterization. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 148-155.	0.6	45
295	A 10376bp deletion of FECH gene responsible for erythropoietic protoporphyria. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 233-236.	0.6	7
296	Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 428-435.	1.0	36
297	Glucose-6-phosphate dehydrogenase deficiency. <i>Lancet</i> , The, 2008, 371, 64-74.	6.3	1,223
298	Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. <i>Haematologica</i> , 2008, 93, 741-752.	1.7	182
299	Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2391-2402.	0.9	40
300	Challenges Associated With Prolonged Survival of Patients With Thalassemia: Transitioning From Childhood to Adulthood. <i>Pediatrics</i> , 2008, 121, e1426-e1429.	1.0	34
301	Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. <i>Haematologica</i> , 2008, 93, 1584-1586.	1.7	113
302	Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/deferioxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox [Kontoghiorghes G], Hemoglobin 2008; 32(1-2):1-15.]. <i>Hemoglobin</i> , 2008, 32, 601-607.	0.4	8
303	Current Status in Iron Chelation in Hemoglobinopathies. <i>Current Molecular Medicine</i> , 2008, 8, 663-674.	0.6	31
304	Pregnancy outcome in patients with $\beta$ -thalassemia intermedia at two tertiary care centers, in Beirut and Milan. <i>Haematologica</i> , 2008, 93, 1586-1587.	1.7	54
305	A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. <i>Haematologica</i> , 2008, 93, 1211-1218.	1.7	55
306	Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in $\beta^2$ -thalassemia. <i>Blood</i> , 2008, 112, 875-885.	0.6	146

#	ARTICLE	IF	CITATIONS
307	Effect of Deferasirox (Exjade®) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial. <i>Blood</i> , 2008, 112, 3881-3881.	0.6	14
308	Beta-thalassemia Intermedia: An Overview. <i>Pediatric Annals</i> , 2008, 37, 322-8.	0.3	12
309	Red Blood Cell Enzyme Disorders: An Overview. <i>Pediatric Annals</i> , 2008, 37, 303-10.	0.3	8
310	Identification of Three Novel Substitutions in the Erythroid Promoter of the HMBS Gene: A New Erythroid Variant of Human Acute Intermittent Porphyria?. <i>Blood</i> , 2008, 112, 4574-4574.	0.6	3
311	Coagulation in the Pathophysiology of Hemolytic Anemias. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 74-78.	0.9	92
312	Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). <i>Blood</i> , 2007, 109, 362-364.	0.6	78
313	Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with $\beta$ -thalassemia. <i>Clinical Therapeutics</i> , 2007, 29, 909-917.	1.1	123
314	Hematologic and Hemato-Oncologic Aspects of Gaucher Disease. <i>Clinical Therapeutics</i> , 2007, 29, S88-S90.	1.1	0
315	K-CL co-transport plays an important role in normal and $\beta$ thalassaemic erythropoiesis. <i>Haematologica</i> , 2007, 92, 1319-1326.	1.7	18
316	Expression of the $\gamma$ -globin gene is sustained by the cAMP-dependent pathway in $\beta$ -thalassaemia. <i>British Journal of Haematology</i> , 2007, 138, 382-395.	1.2	28
317	Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. <i>British Journal of Haematology</i> , 2007, 138, 676-686.	1.2	81
318	$\beta$ -thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. <i>British Journal of Haematology</i> , 2007, 139, 3-13.	1.2	188
319	Growth hormone deficiency (GHD) in adult thalassaemic patients. <i>Clinical Endocrinology</i> , 2007, 67, 790-795.	1.2	38
320	Long-Term Treatment with Deferasirox (Exjade®, ICL670), a Once-Daily Oral Iron Chelator, Is Effective in Patients with Transfusion-Dependent Anemias.. <i>Blood</i> , 2007, 110, 2777-2777.	0.6	10
321	Impact of Dose Adjustments on Serum Ferritin (SF) Levels during Long-Term Treatment with Once-Daily, Oral Deferasirox (Exjade®, ICL670).. <i>Blood</i> , 2007, 110, 2778-2778.	0.6	3
322	Evaluation of Deferasirox (Exjade®, ICL670) Therapy in Patients with Transfusional Iron Overload Who Achieve Serum Ferritin (SF) $\leq$ 1000 ng/mL in Long-Term Studies.. <i>Blood</i> , 2007, 110, 3795-3795.	0.6	6
323	Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 291-299.	0.9	65
324	Gender Differences in Iron Overload and Left Ventricular Function in a Cohort of Thalassemia Major Patients: A Prospective Study of a Single Italian Center Using Cardiovascular Magnetic Resonance.. <i>Blood</i> , 2007, 110, 3819-3819.	0.6	0

#	ARTICLE	IF	CITATIONS
325	cAMP differentially regulates $\hat{\gamma}$ -globin gene expression in erythroleukemic cells and primary erythroblasts through c-Myb expression. <i>Biochemical and Biophysical Research Communications</i> , 2006, 344, 1038-1047.	1.0	33
326	Thalassemia intermedia: Revisited. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 37, 12-20.	0.6	269
327	A large deletion on chromosome 11 in acute intermittent porphyria. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 37, 50-54.	0.6	8
328	Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. <i>Blood</i> , 2006, 107, 3733-3737.	0.6	338
329	A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. <i>Blood</i> , 2006, 107, 3455-3462.	0.6	636
330	Deferasirox: a novel, once-daily oral iron chelator. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 453-460.	0.2	2
331	Co-existence of two functional mutations on the same allele of the human ferrochelatase gene in erythropoietic protoporphyria. <i>Clinical Genetics</i> , 2006, 71, 84-88.	1.0	16
332	A woman with black urine. <i>British Journal of Haematology</i> , 2006, 137, 061127011144004-???	1.2	1
333	Modification of sialidase levels and sialoglycoconjugate pattern during erythroid and erythroleukemic cell differentiation. <i>Glycoconjugate Journal</i> , 2006, 24, 67-79.	1.4	17
334	Changes in erythropoiesis, iron metabolism and oxidative stress after half-marathon. <i>Internal and Emergency Medicine</i> , 2006, 1, 30-34.	1.0	18
335	Unusual severe development of common B lymphoblastic leukemia in Gaucher disease type I. <i>American Journal of Hematology</i> , 2006, 81, 383-384.	2.0	3
336	Removing the Burden—Iron Overload and Deferasirox (ICL670). <i>Oncology &amp; Hematology Review</i> , 2006, 00, 67.	0.2	1
337	Ineffective Erythropoiesis in $\hat{\gamma}$ -Thalassemia Is Characterized by Enhanced Survival Mechanisms That Reduce P21-Mediated Cell Death.. <i>Blood</i> , 2006, 108, 649-649.	0.6	0
338	Deferasirox: a novel, once-daily oral iron chelator. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 453-460.	0.2	0
339	Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. <i>Haematologica</i> , 2006, 91, 873-80.	1.7	210
340	Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. <i>Thrombosis and Haemostasis</i> , 2006, 96, 488-91.	1.8	86
341	Coagulation and Splenectomy: An Overview. <i>Annals of the New York Academy of Sciences</i> , 2005, 1054, 317-324.	1.8	110
342	Exercise capacity in patients with beta-thalassaemia intermedia. <i>British Journal of Haematology</i> , 2005, 131, 278-281.	1.2	12

#	ARTICLE	IF	CITATIONS
343	A point mutation affecting an SP1 binding site in the promoter of the ferrochelatase gene impairs gene transcription and causes erythropoietic protoporphyria. <i>Experimental Hematology</i> , 2005, 33, 584-591.	0.2	20
344	Overcoming the challenge of patient compliance with iron chelation therapy. <i>Seminars in Hematology</i> , 2005, 42, S19-S21.	1.8	40
345	Iron-chelating therapy with the new oral agent ICL670 (Exjade®). <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 289-298.	0.7	78
346	Two Functional Mutations in cis of the Ferrochelatase Gene (FECH) Cause Erythropoietic Protoporphyria (EPP).. <i>Blood</i> , 2005, 106, 3544-3544.	0.6	0
347	Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. <i>Haematologica</i> , 2005, 90, 452-8.	1.7	91
348	Purging iron from the heart. <i>British Journal of Haematology</i> , 2004, 125, 545-551.	1.2	34
349	Hepatocellular carcinoma in the thalassaemia syndromes. <i>British Journal of Haematology</i> , 2004, 124, 114-117.	1.2	147
350	Intrathoracic Masses Due to Extramedullary Hematopoiesis. <i>American Journal of the Medical Sciences</i> , 2004, 328, 299-303.	0.4	26
351	Molecular Analysis of Alpha Hemoglobin Stabilizing Protein (AHSP) in Caucasian Patients with different Beta-Thalassemia Phenotypes.. <i>Blood</i> , 2004, 104, 3770-3770.	0.6	5
352	Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. <i>Haematologica</i> , 2004, 89, 1179-86.	1.7	49
353	Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. <i>Haematologica</i> , 2004, 89, 1187-93.	1.7	772
354	Î²-THALASSEMIA INTERMEDIA FROM SOUTHERN IRAN: IVS-II-1 (Gât'A) IS THE PREVALENT THALASSEMIA INTERMEDIA ALLELE. <i>Hemoglobin</i> , 2002, 26, 147-154.	0.4	44
355	Long-term treatment with oral sildenafil in a thalassaemic patient with pulmonary hypertension. <i>Blood</i> , 2002, 100, 1516-1517.	0.6	54
356	Hematologically Important Mutations: Acute Intermittent Porphyrin. <i>Blood Cells, Molecules, and Diseases</i> , 2002, 28, 5-12.	0.6	9
357	The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. <i>British Journal of Haematology</i> , 2002, 118, 330-336.	1.2	192
358	Tc-99m Sulphur Colloid Scintigraphy in the Assessment of Residual Splenic Tissue after Splenectomy. <i>Clinical Radiology</i> , 2001, 56, 1-4.	0.5	21
359	Membrane-bound iron contributes to oxidative damage of Î²-thalassaemia intermedia erythrocytes. <i>British Journal of Haematology</i> , 2001, 112, 48-50.	1.2	68
360	Non-Transferrin-Bound Iron in Alcohol Abusers. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 1494-1499.	1.4	43

#	ARTICLE	IF	CITATIONS
361	Non-Transferrin-Bound Iron in Alcohol Abusers. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 1494-1499.	1.4	16
362	Molecular analysis of the hydroxymethylbilane synthase (HMBS) gene in Italian patients with acute intermittent porphyria: Report of four novel mutations. , 2000, 15, 480-480.		10
363	Oral Isobutyramide Therapy in Patients with Thalassemia Intermedia: Results of a Phase II Open Study. <i>Blood Cells, Molecules, and Diseases</i> , 2000, 26, 105-111.	0.6	41
364	Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in $\beta^2$ -thalassemia intermedia. <i>Transfusion Science</i> , 2000, 23, 245-246.	0.6	22
365	Chronic non-spherocytic haemolytic disorders associated with glucose-6-phosphate dehydrogenase variants. <i>Best Practice and Research in Clinical Haematology</i> , 2000, 13, 39-55.	0.7	47
366	Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?. <i>The Hematology Journal</i> , 2000, 1, 153-158.	2.0	62
367	Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. <i>British Journal of Haematology</i> , 2000, 111, 467-473.	1.2	244
368	Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. <i>British Journal of Haematology</i> , 2000, 111, 461-466.	1.2	66
369	Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythrophagocytosis in $\beta^2$ -thalassaemia intermedia. <i>British Journal of Haematology</i> , 1999, 104, 504-512.	1.2	76
370	Carbohydrate-deficient transferrin, a sensitive marker of chronic alcohol abuse, is highly influenced by body iron. <i>Hepatology</i> , 1999, 29, 658-663.	3.6	74
371	Butyrate Trialsa. <i>Annals of the New York Academy of Sciences</i> , 1998, 850, 110-119.	1.8	12
372	Survival and Disease Complications in Thalassemia Major. <i>Annals of the New York Academy of Sciences</i> , 1998, 850, 227-231.	1.8	312
373	High prevalence of the His63Asp HFE mutation in italian patients with porphyria cutanea tarda. <i>Hepatology</i> , 1998, 27, 181-184.	3.6	195
374	cDNA Cloning and Functional Characterization of the Mouse Ca <sup>2+</sup> -gated K <sup>+</sup> Channel, mlk1. <i>Journal of Biological Chemistry</i> , 1998, 273, 21542-21553.	1.6	183
375	A Multicenter Prospective Study on the Risk of Acquiring Liver Disease in Anti-Hepatitis C Virus Negative Patients Affected From Homozygous $\beta^2$ -Thalassemia. <i>Blood</i> , 1998, 92, 3460-3464.	0.6	71
376	A Multicenter Prospective Study on the Risk of Acquiring Liver Disease in Anti-Hepatitis C Virus Negative Patients Affected From Homozygous $\beta^2$ -Thalassemia. <i>Blood</i> , 1998, 92, 3460-3464.	0.6	2
377	The expression of uridine diphosphate glucuronosyltransferase gene is a major determinant of bilirubin level in heterozygous beta-thalassaemia and in glucose-6-phosphate dehydrogenase deficiency. <i>British Journal of Haematology</i> , 1997, 99, 437-439.	1.2	87
378	Genetic hemochromatosis in Italian patients with prophyria cutanea tarda: possible explanation for iron overload. <i>Journal of Hepatology</i> , 1996, 24, 564-569.	1.8	47

#	ARTICLE	IF	CITATIONS
379	Carbohydrate-Deficient Transferrin in Alcohol and Nonalcohol Abusers with Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 1995, 19, 1525-1527.	1.4	32
380	Molecular characterisation of the glucose-6-phosphate dehydrogenase (G6PD) Ferrara II variant. <i>Human Genetics</i> , 1995, 95, 440-442.	1.8	15
381	G6PD Ferrara I has the same two mutations as G6PD A(-) but a distinct biochemical phenotype. <i>Human Genetics</i> , 1994, 93, 139-142.	1.8	15
382	Biochemical and molecular characterization of a new sporadic glucose-6-phosphate dehydrogenase variant described in Italy: G6PD Modena. <i>British Journal of Haematology</i> , 1994, 87, 209-211.	1.2	8
383	Molecular characterisation of an Italian G6PD variant responsible for chronic non- $\epsilon$ spherocytic haemolytic anaemia. <i>Clinical Genetics</i> , 1994, 46, 357-359.	1.0	4
384	Iron status in red cell pyruvate kinase deficiency: study of Italian cases. <i>British Journal of Haematology</i> , 1993, 83, 485-490.	1.2	62
385	Linkage analysis of 6p21 polymorphic markers and the hereditary hemochromatosis: localization of the gene centromeric to HLA-F. <i>Human Molecular Genetics</i> , 1993, 2, 571-576.	1.4	40
386	Uremic Inhibitors of Erythropoiesis: A Study during Treatment with Recombinant Human Erythropoietin. <i>American Journal of Nephrology</i> , 1992, 12, 9-13.	1.4	6
387	Functional roles of the ferritin receptors of human liver, hepatoma, lymphoid and erythroid cells. <i>Journal of Inorganic Biochemistry</i> , 1992, 47, 219-227.	1.5	64
388	Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association. <i>Hepatology</i> , 1992, 16, 1322-1326.	3.6	298
389	Binding and suppressive activity of human recombinant ferritins on erythroid cells. <i>American Journal of Hematology</i> , 1992, 39, 264-268.	2.0	15
390	Association of Hereditary Spherocytosis and Idiopathic Hemochromatosis: A Synergistic Effect in Determining Iron Overload. <i>American Journal of Clinical Pathology</i> , 1986, 86, 645-649.	0.4	35
391	Non-specific Iron in Patients with Beta-thalassaemia Trait and Chronic Active Hepatitis. <i>Scandinavian Journal of Haematology</i> , 1981, 26, 161-167.	0.0	11
392	Thalassemia Is Paradoxically Associated with a Reduced Risk of In-Hospital Complications and Mortality in COVID-19: Data from an International Registry. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0